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WestNileVirus is becoming awidespreadpathogen, infecting
people on at least four continentswith no effective treatment for
these infections or many of their associated pathologies. A key
enzyme that is essential for viral replication is the viral protease
NS2B-NS3, which is highly conserved among all flaviviruses.
Using a combination of molecular fitting of substrates to the
active site of the crystal structure of NS3, site-directed enzyme
and cofactor mutagenesis, and kinetic studies on proteolytic
processing of panels of short peptide substrates, we have identi-
fied important enzyme-substrate interactions that define sub-
strate specificity for NS3 protease. In addition to better under-
standing the involvement of S2, S3, and S4 enzyme residues in
substrate binding, a residue within cofactor NS2B has been
found to strongly influence the preference of flavivirus pro-
teases for lysine or arginine at P2 in substrates. Optimization of
tetrapeptide substrates for enhanced protease affinity and proc-
essing efficiency has also provided important clues for develop-
ing inhibitors of West Nile Virus infection.
WestNile virus (WNV)4 is amember of the Flavivirus genus,
which contains many significant human pathogens, including
dengue virus (Den), Japanese encephalitis virus (JE), and yellow
fever virus (YF), and was first isolated in 1937 from Uganda’s
West Nile province. WNV has subsequently been found in
regions ofAfrica, theMiddle East, Europe, Russia, westernAsia,
and Australia (less severe subtype Kunjin) and most recently in
North America (1). WNV is transmitted by Culex mosquitoes
from avian reservoir hosts to vertebrate dead end hosts, includ-
ing humans and horses (2). Human infection is generally
asymptomatic or causes a mild febrile disease, West Nile fever.
However, more recent infections of WNV have also been asso-
ciatedwith higher rates of severe neurological disease and fatal-
ities, particularly among the elderly (2). Since the introduction
of WNV into New York in 1999, the virus has spread rapidly
throughout North America, infecting over 19,000 people and
causing more than 700 fatalities (see the Center for Disease
Control and Prevention site on the World Wide Web at www.
cdc.gov/ncidod/dvbid/westnile/index.htm). Currently there is
no vaccine or antiviral therapy for the prevention or treatment
of humanWNV infection (1).
WNV is a small, enveloped virus with a single-stranded, pos-
itive sense 11-kbRNAgenome,which encodes a single polypro-
tein precursor. This polyprotein must be cleaved co- and post-
translationally to produce 10 functional proteins: three
structural (C, prM, and E) and seven nonstructural (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Translation of the
viral polyprotein is membrane-associated with host proteases
cleaving junctions within the lumen of the endoplasmic reticu-
lumand theGolgi, whereas a viral protease encodedwithinNS3
cleaves at the junctions NS2A/NS2B, NS2B/NS3, NS3/NS4A,
andNS4B/NS5 and also internal sites within C, NS3, andNS4A
(Fig. 1) (3). Cleavage at these sites by the NS3 protease is essen-
tial for viral replication, so the protease is a potential therapeu-
tic target (4–7).
NS3 is amultifunctional protein, the protease comprising the
N-terminal third and nucleotide triphosphatase, RNA triphos-
phatase, and helicase components comprising the remainder
(8–10). NS3 is a trypsin-like serine protease with a classical
catalytic triad (His-51, Asp-75, Ser-135) (11) and is highly spe-
cific for substrates with dibasic P1 and P2 components and a
small amino acid at P1. This recognition sequence is highly
conserved throughout flaviruses (12); however, different flavi-
viruses prefer either Lys or Arg at P2. Although Den and YF
NS3 proteases predominantly recognize Arg at P2, WNV pro-
tease recognizes Lys at P2 (Table 1). The activity of flavivirus
NS3 proteases is dependent on an NS2B cofactor, with trunca-
tion studies in Den2 having shown that a central 40-amino acid
hydrophilic domain is sufficient for activity (13). The flanking
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hydrophobic domains within NS2B are likely to function in
promoting membrane association of NS2B-NS3 (14).
Due to their pivotal roles in both normal physiology and dis-
ease, proteases are increasingly attracting interest as pharma-
ceutical targets (15). Since early successes in human immuno-
deficiency virus chemotherapy (human immunodeficiency
virus-protease inhibitors) and in the treatment of high blood
pressure (angiotensin-converting enzyme (ACE) inhibitors), a
large number of new protease inhibitors have entered clinical
trials (16). One reason for the drug potential of proteases is the
relatively predictable way in which they recognize their substrates
and inhibitors inextended (-strand)conformations (4, 17).There
arenoknownexamples of proteolytic processingof peptide-hel-
ices, -sheets, or -turns. Greater access to three-dimensional
structures for proteases (over 1500 in the Protein Data Bank) has
also facilitated hybrid structure/substrate-based drug design (5).
Recently reported crystal structures for NS2B/NS3 proteases
of both WNV and Den2 (6) provide new structural insights to
flaviviral proteases in ligand-bound conformations. An earlier
homology model of the WNV protease (7), derived from the
crystal structures of a highly homologous dengue NS3 protease
without NS2B cofactor (18) and a less homologous hepatitis
NS3 with bound NS4A cofactor (19), differs significantly from
the crystal structure of WNV NS2B-NS3. This has prompted a
reexamination now of some of the previous mutagenesis data
(20). The reported WNV protease crystal structure shows an
N-capped tetrapeptide aldehyde inhibitor bound in the sub-
strate-binding cleft as a loop (instead of the commonly
observed -strand conformation) with the “P5” capping ben-
zoyl residue sitting on top of the P1 residue. It therefore seemed
unlikely that this ligand had the same binding mode as sub-
strates beyond P1 and P2.
In previous kinetic studies using short hexapeptide p-nitroa-
nilide substrates derived from endogenous polypeptide cleav-
age sites, we found no preference ofWNV protease for specific
residues except at P1 and P2 (7). However, more recent studies
using nonnative dengue hexapeptide and decapeptide5 and tet-
rapeptide and octapeptide (21) substrate sequences have sug-
gested opportunities for enhancing substrate affinity for flavi-
viral proteases using nonnative or nonproteinogenic amino
acids with hydrophobic (Nle, Leu) residues at P4 and a basic
(Lys  Arg) residue at P3, a feature not seen in suboptimal
native sequences. Using a combination of computer docking of
substrates into the enzyme crystal structure, site-directed
mutagenesis of the protease (Fig. 1), and kinetic studies of the
processing of tetrapeptide substrates, we have focused the pres-
ent study on increasing substrate affinity and processing effi-
ciency, identifying the enzyme residues likely to be involved in
binding to the P2–P4 positions of substrates, and taking early
steps toward potent substrate-based nonpeptidic inhibitors by
incorporating unnatural amino acids in tetrapeptide substrates.
EXPERIMENTAL PROCEDURES
para-Nitroanilide (pNA) Substrate Synthesis—pNA sub-
strates were synthesized according to the general method of
Abbenante et al. (22) and characterized by analytical high per-
formance liquid chromatography, mass spectrometry, and
NMR (see supplemental material).
Modeling of Substrates into the NS3 Crystal Structure—The
crystal structure of West Nile virus NS2B/NS3 protease (Pro-
tein Data Bank code 2fp7) was prepared for docking by adding
protons using InsightII (version 2000; Accelrys Inc.). Substrates
were assembled using the Biopolymer and Sketcher modules
within InsightII and minimized using Discover. All substrate
docking experiments were conducted using GOLD version
2.1.2 (23). Hydrogen bonding and distance constraints were
used to align the substrate within the active site as follows. The
P1 Arg residue was positioned as observed for the correspond-
ing residue in the aldehyde inhibitor complex (Protein Data
Bank code 2fp7) (24), using a distance constraint of 3.5 1.5 Å
between the Arg -carbon and the aromatic -carbon of Tyr-
161 in the S1 pocket. This positions the positive charge of the
arginine optimally for a -cation interaction but also enables a
charge-charge interaction with Asp129. A hydrogen bond
between the P2 Lys z-NH3 and the Asn-152 side-chain car-
bonyl oxygen was used to anchor P2 in the shallow solvent-
exposed S2 pocket, as predicted in earlier modeling work (7)
and later verified experimentally (24). Hydrogen bond con-
straints for critical substrate backbone-enzyme interactions
between NS3-Gly-153 carbonyl oxygen and substrate P3 NH,
Gly-153 NH and substrate P3 carbonyls, and Gly-151 carbonyl
oxygen and Arg P1 NHwere also used. No constraints on the
position of P3 and P4 side chains were used. For the larger
2-naphthoyl residue in 2-naphthoyl-KKR-pNA, the docking
(Fig. 2) produced poses with a high degree of steric clash in the
vicinity of S4. In these cases, the docking poses wereminimized
with the enzyme backbone either fixed or tethered and the
enzyme side chains and the entire substrate allowed to move
using Discover (Accelrys).
Plasmid Construction—The expression plasmid pQE9WNV
CF40.Gly.NS3pro, previously generated from WNV (strain
NY99-4132) (10), was used as a template for site-directed
mutagenesis. The site-directed mutations in NS2B (V75A,
V75F, N84A, N84D, N84E, N84L, N84S, Q86A, Q86E, Q86L,
L87A, and L87F) and NS3 (T111F, T111L, V154F, V154L,
I155F, M156A, I162F, A164S, A164V, and V166L) were
inserted by amplifying the entire plasmid with PCR using Phu-
sionTMpolymerase (Finnzymes) togetherwith a pair of partially
overlapping primers (supplemental material). The template
plasmid was digested with DpnI at 37 °C for 1 h. The PCR-
amplified plasmid was then used to transform Escherichia coli
strain XL10 Gold competent cells, which were grown in the
presence of 100 g/ml ampicillin, the expression plasmid was
purified, and sequences were confirmed by automated analysis.
Enzyme Expression and Purification—The pQE9 vector was
used to allow high level, inducible expression of N-terminal
His6-tagged recombinant proteins. Cultures of E. coli strain
SG13009 transformed with the expression plasmids containing
the site-directed mutations were grown in 2  25 ml of LB
medium containing 100 g/ml ampicillin and 25 g/ml kana-
mycin at 37 °C until the A600 reached 0.5. Expression of the
recombinant protein was induced by the addition of isopropyl
-D-thiogalactopyranoside to a final concentration of 0.3 mM
and incubated for an additional 3 h at 22 °C. Cells were then5 L. Juliano, personal communication.
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harvested by centrifugation at 4500 g for 10min and stored at
20 °C. For protein purification, the cell pellets were thawed
and resuspended in 1 ml of lysis buffer (50 mM HEPES, pH 7.5,
300 mM NaCl, 10 mM imidazole, 5% glycerol). To prevent pro-
teolytic cleavage of protein during lysis and purification, the
following protease inhibitors were added to give the final con-
centrations of 1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml
benzamidine, and 1 mM phenylmethylsulfonyl fluoride. Resus-
pended cells were lysed by sonication, and insoluble products
were pelleted by centrifugation at 27,000  g for 20 min. The
recombinant proteases were purified by affinity chromatogra-
phy using anN-terminal His6 tag on
Ni2 nitrilotriacetic acid-agarose.
Resin (0.5 ml) was pre-equilibrated
with 10 ml of column buffer (50 mM
HEPES, pH 7.5, 300 mM NaCl, 10
mM imidazole, 5% glycerol), and
then the resin was removed and
mixed with the supernatant of the
cell lysates. These mixtures were
incubated at 4 °C on a shaker for 30
min to allow the His-tagged protein
to bind to the Ni2 column. Resin
was pelleted at low speed (100 g),
and the buffer was removed. The
resin was washed with 3  5 ml of
column buffer containing 50 mM
imidazole, and the proteins were
eluted into a single 300-l fraction
with column buffer containing 500
mM imidazole. Purification was
confirmed by 12% SDS-PAGE.
Enzymatic Characterization and
Substrate Analysis—Purified recom-
binant protease, WNV CF40.Gly.
NS3pro, and site-directed mutants
were assayed against tetrapeptide
(Ac-LKKR-pNA) and hexapeptide
(Ac-LQYTKR-pNA) substrates cor-
responding toP6–P1of cleavage sites
in the endogenous substrates but
with a chromogenic pNA group at
the P1 position. Cleavage of pNA
from the peptides byWNVprotease
produced a yellow color that
allowed monitoring at 405 nm. The
assay was conducted in a 96-well
plate, with a final reaction volume of
200 l containing 0.25 or 0.5 M
recombinant protease, using opti-
mized conditions (final concentra-
tion of 50 mM glycine-NaOH, pH
9.5, 30% glycerol, and 1mMCHAPS)
(7). Eight different substrate con-
centrations, each in triplicate, were
used for determining kinetic con-
stants. After preincubation in sepa-
rate wells (10 min, 37 °C), catalysis
was initiated by mixing substrate with enzyme-buffer solution
by automatic shaking for 5 s. The optical density was measured
at 405 nm every 11–30 s for 210 s to 30 min (depending on
activity) in a SpectraMax 250 reader, and the average change in
millioptical density/min was calculated. For low substrate con-
centration, where there was a visible loss in activity over time,
only the first five points were used to calculate the average change
in millioptical density/min. Kinetic parameters were calculated
from weighted nonlinear regression of the initial velocities as a
function of the eight substrate concentrations using Graphpad
Prism 4 software. The parameters kcat,Km, and kcat/Kmwere cal-
FIGURE 1. Flavivirus polyprotein processing. A, the upper schematic shows the sites cleaved by host proteases
(block arrows) and virus-encoded NS2B/NS3 protease (open arrows). The proteolytic domain of NS3 and the NS2B
cofactor are shaded. The schematic below shows this region expanded and the recombinant construct used in this
study. Featuresof theNS2B-NS3procomplex include thecleavagesite (openarrow), thecatalytic triad (asterisks), the
hydrophobicdomainsofNS2B (solidboxes), and theminimum40-aminoacidcofactordomain required for catalytic
activity. The construct CF40.gly.NS3pro comprises the essential 40-amino acid domain of NS2B linked to the NS3
proteasedomainbya flexibleglycine linker (Gly4,Ser,Gly4).B, sequenceofwild typeWNVNS2Bbetweenresidues71
and 90 (top sequence) and the residuesmutated in this study.C, sequence ofwild typeWNVNS3between residues
111 and 170 (top sequence) and the residuesmutated in this study.
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culated assuming Michaelis-Menten equilibrium kinetics, v 
Vmax[S]/([S]Km). Triplicatemeasurements were taken for each
data point, andmeans S.E. are reported.
RESULTS
Predicted Substrate-Enzyme Interactions—The reported
crystal structure of WNV NS3 protease in association with the
cofactor domain of NS2B has increased the understanding of
themechanismof substrate binding and protease activity. Since
the enzyme was also bound to a tetrapeptide-aldehyde inhibi-
tor, it was possible to observe enzyme residues that interact
with P1 and P2 side chains. However, because the inhibitor was
not bound in the extended -strand conformation typical of
substrate-protease interactions (4, 17), enzyme contacts with
substrate beyond P1 and P2 positions could not be deduced
from that crystal structure. In this work, we sought to dissect
critical substrate interactions with enzyme at S2, S3, and S4.
Cleavage sites forWNV protease vary considerably between P6
and P3 in native polypeptide substrates (e.g. DPNRKR2GW
(NS2A-NS2B), LQYTKR2GG (NS2B-NS3), FASGKR2SQ
(NS3-NS4A), KPGLKR2GG (NS4A-NS5)), with polar, acidic,
basic, and hydrophobic residues all tolerated at P6–P3
positions.
To predict protease residues that are important for substrate
binding, we conducted molecular modeling experiments using
GOLD to dock tetrapeptide pNA substrates into the crystal
structure of the WNV NS2B/NS3 protease (Protein Data Bank
code 2fp7). The tetrapeptide substrate Ac-LKRR-pNA span-
ning P4–P1 had been previously identified (21) as optimal for
dengue protease and, since we knew that WNV elicited a pref-
erence for Lys over Arg at P2, our docking studies began with
the tetrapeptide substrate Ac-LKKR-pNA. Docking flexible
molecules such as peptides into rigid solid state structures of
proteases is notoriously difficult due to inadequate sampling of
conformational space and insufficiently minimized docked
poses (25) and because GOLD does not allow for cooperative
interactions or enzyme flexibility. To generatemore valid dock-
ing results, hydrogen bonding and distance constraints were
used to restrict the substrate to -strand-like conformations
that are more biologically relevant (4, 5).
The crystal structure of WNV protease suggests that in
addition to substrate-binding residues within NS3, residues
within the NS2B cofactor also interact with substrate. Molecu-
lar docking (Fig. 2A) suggests that the P3Lys side chain does not
occupy a well defined S3 pocket in the enzyme but instead is
largely solvent-exposed and binds in a shallow groove extend-
ing toward S1. This hydrophobic region is perhaps the reason
that the four endogenous cleavage sequences contain a range of
residues at P3 (Arg, Thr, Gly, and Leu). In all cases, there are
hydrophobic elements in proximity to the main chain that are
able to interact with the hydrophobic wall of the groove (e.g.
Ile-155) as well as being able to accommodate both charged and
polar side-chain termini directed outward into solvent. Asn-
152 is hypothesized to be the S2 hydrogen bond acceptor of the
P2 Lys side chain (7). On the opposite side of the substrate
binding cleft to S2 is a hydrophobic surface patch consisting of
Val-154,Met-156, and cofactor residue Leu-87. The hydropho-
bicity of these residues is highly conservedwithin the Flavivirus
genus, and theymost likely constitute one side of the shallow S4
pocket. The cofactor residue Gln-86 is observed in the crystal
structure to participate in a hydrogen bond with the P3 Lys-
NH3 of an aldehyde inhibitor bound in an unusual conforma-
tion, but, since this residue is poorly conserved among the fla-
viviruses, the side chain is probably not important for substrate
binding. Farther away, the cofactor residue Val-75 may make
interactions with P5 or P6. However, it is difficult to predict
how substrate might extend into and bind at this position. Also
of interest is the cofactor residue Asn-84, which appears to
make a hydrogen bond with the P2 Lys. This residue is semi-
conserved within the Flavivirus genus as either a polar or neg-
atively charged residue (Asn, Ser, Thr, Asp, and Glu).
FIGURE 2. Docking of substrates into the WNV NS2B/NS3 crystal struc-
ture.A, active site ofWNVNS2B/NS3 crystal structure (ProteinDataBank code
2fp7). The Connolly surface of NS3 is in gray, with the catalytic triad in white
and the cofactor NS2B in yellow; asparagine 84 of the cofactor is shown in
blue. The docked extended conformation of Ac-LKKR-pNA is represented by
the green stick structurewith nitrogen andoxygen atoms colored blue and red,
respectively. The crystallographically determined tetrapeptide inhibitor ben-
zoyl-(Nle)KRR-H is shown in black. B, docked andminimized extended confor-
mation of naphthoyl-capped tripeptide substrate 2-naphthoyl-KKR-pNA. The
Connolly surface of NS3 is again in gray, with the cofactor NS2B in yellow.
Leucine 87 of the cofactor NS2B is shown in blue, and valine 154 of NS3 is
shown in purple.
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Docking of 2-naphthoyl-KKR-pNA generally resulted in two
docking poses. One had the bulky naphthoyl residue in the S1
pocket, resulting in a nonextended conformation reminiscent
of the turnlike structure of the inhibitor aldehyde in the pub-
lished crystal structure. The other had the aromatic residues
interacting with hydrophobic enzyme residues at S4 but with
some resultant steric clashes. Docking with GOLD used an
explicit rigid protein method that is frequently inadequate for
proteases, since they often display a high degree of active site
plasticity (25). In this case, we took the docked poses where the
2-naphthoyl residue occupied the conventional extended con-
formation in the S4 site and used a combination of molecular
dynamics and energy minimization to investigate possible
induced fit binding modes. Fig. 2B shows one minimized dock-
ing pose where the small S4 pocket has been enlarged by a
subtle movement of the side chains of Ile-155 and Val-154 in
NS3 andVal-75, Val-77, andLeu-87 ofNS2B.After thesemove-
ments, the now slightly deeper S4 pocket is additionally defined
by two residues (Phe-116 from NS3 and Phe-85 from NS2B)
that make favorable aromatic-aromatic interactions with the
naphthoyl ring.
Regarding the orientation of the substrate in the active site of
the enzyme, the model suggests that the carbonyl carbon of the
substrate scissile amide was 2.5–2.8 Å from the catalytic serine
hydroxyl and in an orientation reminiscent of aMichaelis com-
plex, despite no explicit restraints being used to fix it.
Following these substrate-docking modeling experiments,
we prepared a number of site-directed mutants with residue
substitutions in both NS3 and NS2B to test the predicted
interactions. In parallel, we synthesized a library of chromo-
genic pNA substrates, designed around the optimal sub-
strate used for our docking studies, and examined their proc-
essing kinetics by both wild type and mutant NS2B/NS3
West Nile Virus proteases.
Cofactor-Substrate Correlations—The crystal structure of
WNV NS2B/NS3 protease revealed that Asn-84 of the NS2B
cofactor is within hydrogen bonding distance of the P2 Lys of
the bound ligand. Asn-84 is located within a highly conserved
region of the cofactor, the Gly residue on the N-terminal side is
completely conserved, and the third residue on the C-terminal
side is a highly conserved hydrophobic Leu or Ile. Although the
residue homologous with NS2B Asn-84 in other flaviviruses is
variable, it is always polar or negatively charged (Table 1). This
is of particular interest, because there appears to be an associ-
ation between this residue and either Lys or Arg at P2 in native
cleavage sequences. An Asn residue is at this position in WNV
and St. Louis encephalitis (SLEV) proteases, corresponding to a
preferred Lys at P2 of native substrates. However, in the pro-
teases of all four serotypes of dengue, there is either Ser or Thr
at this position matched by Arg at P2 in native substrates. The
presence of Gln at P2 for one of the crucial cleavage sites
(NS2B-NS3) suggests a requirement for a hydrogen-bonding
pair and not a charge-charge interaction pair.
Specific partnering between cofactor and substrate is also
seenwhen a negatively charged residue is present in the homol-
ogous position of the cofactor. In YF, a Glu at this position in
the cofactor always corresponds with Arg at P2 in the native
cleavage site. In JE, Murray Valley encephalitis (MVE), Zika
virus (ZIKV), and Bussuquara virus (BSQV), an Asp is matched
by a P2 Lys predominantly in the native cleavage site (Table 1).
On the other hand, proteases of flaviviruses that are transmit-
ted by ticks, tick-borne encephalitis (TBE) and Langat virus
(LGTV), do not show the same preference as WNV and St.
Louis encephalitis proteases. Despite Asn at the homologous
position in the cofactor for TBE and LGTV proteases, in all
cases they recognize Arg at P2 in the cleavage sites of their
native substrates, compared with Lys at P2 in substrates for
SLEV and WNV proteases. The tick-borne flaviviruses form a
TABLE 1
Flavivirus cleavage sequences and cofactor homology
Mosquito-borne flaviviruses includeWest Nile virus (WNV), St. Louis encephalitis (SLEV), dengue virus subtypes 1–4 (Den1, Den2, Den3, Den4), yellow fever virus (YF),
Japanese encephalitis virus (JE), Murray Valley encephalitis (MVE), Zika virus (ZIKV), and Bussuquara virus (BSQV). Tick-borne flaviviruses include Langat virus (LGTV)
and tick-borne encephalitis virus (TBE). The first column shows the alignment of the region of NS2B involved in substrate binding, whereas the next four columns show the
native flavivirus cleavage sequences (P4–P1). The final column shows the degree of homology between the various flaviviruses and theWNVNS2B 40-amino acid cofactor
domain and the NS3 protease domain. Residues shown in green and yellow designate homology. The residue shown in boldface type and designated by the asterisk is
believed to interact with P2. A P2 arginine residue is shown in blue, and a P2 lysine is shown in red.
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cluster distinct from themosquito-borne flaviviruses, and there
are significant amino acid changes between the two subgroups.
Therefore it is likely that there are other significant differences
within the substrate binding cleft thatmay account for the pref-
erence of a P2 Arg in substrates. To investigate the role of
NS2B-84, various mutant proteases of WNV were produced
with this residue altered to homologous residues from other
flaviviruses (see below).
Substrate Design andKinetic Processing—Kinetic parameters
for proteolytic processing of modified substrates by WNV
NS2B-NS3 protease are shown in Table 2. Initially, our hypoth-
esis was that hydrophobic residues at P4 could interact with the
surface-exposed hydrophobic region bounded by Val-154 and
Met-156 of NS3 and Leu-87 of NS2B. We therefore prepared
substrates based on Ac-XKKR-pNA, where X represents a
hydrophobic unnatural amino acid (Table 2, entries 1–9, and
Fig. 3). Most of the examined substrates had Km and kcat values
comparable with those of Ac-LKKR-pNA, with a -branched
residue t-butylglycine that induces steric crowding on the pep-
tide main chain being most detrimental to binding and proc-
essing. Substrate processing was least efficient for this and
similar -branched residues like aminoisobutyric acid and
cyclohexylglycine (Table 2, entries 3, 9, 10). The substrate
containing 2-amino-octanoic acid Aoc gave the highest kcat
of any substrate in this study, but this was tempered by a
slightly lower affinity (Km). Replacing the flexible Ac-P4
moiety with a rigid 2-naphthoyl group resulted in the highest
affinity substrate (Km 25 M) with a slightly lower kcat but
the most efficient processing (kcat/Km  42,603 M1 s1).
Taken together, these results confirm the hypothesis that
hydrophobic interactions are the key to interactions
between P4 of substrates and S4 of enzyme.
The observation that substrates bearing the bulky 2-naph-
thoyl group at P4 possessed enhanced Km but lower kcat values
may be attributable to an induced fit at P4/S4. As found in the
FIGURE 3. Natural and unnatural hydrophobic amino acids used in P4
mutant substrate synthesis.
TABLE 2
Enzyme kinetics of substrates modified at P4, P3, and P2
2-Naph, 2-naphthoyl; 3Pya, 3-pyridylalanine; 4Pya, 4-pyridylalanine; nPhe, p-nitrophenylalanine; aPhe, p-aminophenylalanine. Enzyme kinetic datawere obtained using the
in vitro enzyme assay, and each data point represents the mean of triplicate measurements S.E.
Substrate Km kcat kcat/Km
M s1 M1 s1
P4 variants
1. Ac-Leu-Lys-Lys-Arg-pNA 54.6 5.1 1.64 0.04 30,117 2248
2. Ac-Nle-Lys-Lys-Arg-pNA 80.7 6.7 2.35 0.06 29,091 1831
3. Ac-Nva-Lys-Lys-Arg-pNA 67.3 6.8 2.36 0.08 34,997 2696
4. Ac-Chg-Lys-Lys-Arg-pNA 81.9 8.8 1.78 0.06 21,735 1799
5. Ac-Cha-Lys-Lys-Arg-pNA 69.9 8.1 2.28 0.04 32,599 2920
6. Ac-Aib-Lys-Lys-Arg-pNA 79.7 6.2 1.60 0.04 20,050 1186
7. Ac-Tbg-Lys-Lys-Arg-pNA 134.2 8.4 1.74 0.04 12961 590
8. Ac-Aoc-Lys-Lys-Arg-pNA 75.5 10.5 2.51 0.11 33,188 3582
9. 2-Naph-Lys-Lys-Arg-pNA 25.4 4.4 1.08 0.06 42,603 5472
P3 variants
10. Ac-Leu-3Pya-Lys-Arg-pNA 88.7 9.4 0.50 0.02 5601 419
11. Ac-Leu-4Pya-Lys-Arg-pNA 254.8 19.5 0.90 0.03 3536 178
12. Ac-Leu-hArg-Lys-Arg-pNA 62.5 5.8 1.18 0.03 18,960 1374
13. Ac-Leu-nPhe-Lys-Arg-pNA 254.1 21.0 0.72 0.03 2817 151
14. Ac-Leu-Cit-Lys-Arg-pNA 208.6 16.7 1.44 0.05 6904 372
15. Ac-Leu-Orn-Lys-Arg-pNA 105.5 7.7 1.79 0.05 16,999 841
16. Ac-Leu-aPhe-Lys-Arg-pNA 141.3 13.8 0.75 0.03 5306 369
17. 2-Naph-Cit-Lys-Arg-pNA 21 4.0 0.32 0.02 15,148 2168
18. 2-Naph-Orn-Lys-Arg-pNA 38 5.7 0.98 0.04 25,743 3184
19. 2-Naph-3Pya-Lys-Arg-pNA 65.8 5.1 0.96 0.03 14617 731
20. 2-Naph-hArg-Lys-Arg-pNA 48 11 0.11 0.01 2294 362
P2 variants
21. 2-Naph-Lys-Cit-Arg-pNA 3423 1306 0.43 0.09 127 23
22. 2-Naph-Lys-Orn-Arg-pNA 36.8 3.8 1.58 0.05 42,889 3152
23. 2-Naph-Lys-Arg-Arg-pNA 43.4 4.6 0.89 0.04 20,382 1338
24. 2-Naph-Lys-hArg-Arg-pNA 26.7 3.7 0.59 0.03 22,066 1953
25. 2-Naph-Lys-AcLys-Arg-pNA 2303 544 0.30 0.03 131 17
26. 2-Naph-Lys-aPhe-Arg-pNA No activity
27. 2-Naph-Lys-nLeu-Arg-pNA No activity
28. 2-Naph-Lys-Phe-Arg-pNA No activity
29. 2-Naph-Orn-Orn-Arg-pNA 22.9 3.4 0.27 0.01 11,899 1367
30. 2-Naph-Cit-Orn-Arg-pNA 100.7 8.4 0.57 0.02 5612 260
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docking studies on this class of substrate, allowing the enzyme
side chains to move produced better binding modes at this site.
However, this requirementmay contribute to lower overall cat-
alytic efficiency by causing a repositioning of the scissile bond
relative to the catalytic machinery, or alternatively, if the
enzyme moves back into a “native” conformation after sub-
strate hydrolysis, it may affect the departure of the N-terminal
cleavage fragment from the active site (koff).
We next examined whether nonproteinogenic amino acids
could be incorporated at P3 (Table 2, entries 10–20). In light of
the finding that 2-naphthoyl was a higher affinity replacement
for Ac-Leu, a number of P3 mutants were examined with both
Ac-Leu and 2-naphthoyl at P4. Interestingly, all of the changes
made in this panel of substrates (Fig. 4 and Table 2, entries
10–19) resulted in lower overall kcat/Km values, primarily due
to large reductions in kcat. Substitution of 2-naphthoyl for Ac-
Leu at P4 contributed a 10-fold improvement in Km for sub-
strates containing citrulline at P3, 3-fold for ornithine, 2-fold
for homoarginine, but negligible improvement for 3-pyridylala-
nine. These gains, however, came at a cost of a 4-fold reduction
in kcat for citrulline, 2-fold for ornithine, 10-fold for homoargi-
nine, but surprisingly a 2-fold gain in kcat for 3-pyridylalanine. It
therefore appears that a protonated amine is not absolutely
required for affinity at P3, since the citrulline mutant substrate
showed the best Km. However, this required the presence of
2-naphthoyl at P4 for a cooperative effect. The effect of length-
ening the spacer between the positive chargedArg and themain
chain (hArg) was minor when P4 was Ac-Leu but detrimental
when 2-naphthoyl capped the substrate. This clearly indicates
that the naphthoyl substituent, possibly due to induced fit
effects, had a major effect on the mode of binding of the sub-
strates at the neighboring S3 enzyme subsite.
For the study of P2 mutant substrates (Table 2, entries
21–30), 2-naphthoyl was invariant at P4, and P3 was initially
Lys. As for dengue protease (21), the presence of a basic amine
at this positionwas found to be essential, with aromatic amines,
capped amines, and hydrophobic residues not being tolerated.
Only ornithine, with its high affinity and good kcat, was a satis-
factory replacement for Lys, although homoarginine with the
longer side chain before the positive charge, had comparable
activity, with an increase in Km and a decrease in kcat. The
effects of cooperative changes were then examined using orni-
thine at P2 and either citrulline or ornithine at P3. As predicted,
there was no cooperative gain in substrate fitness by these dou-
ble mutations. The Orn-Orn mutant possessed a good Km but
had a further reduction in kcat, with Cit-Orn conferring inferior
Km and kcat. It is interesting to note that WNV protease pro-
cessed substrates with a P2 Lys over 2-foldmore efficiently than
those with a P2 Arg.
Kinetic Studies of Mutant WNV NS3 and NS2B—To test the
importance of specific enzyme residues on catalytic activity, we
constructed 12 recombinant proteases, incorporating muta-
tions of NS3 (T111F, T111L, D129A, D129E, V154F, V154L,
I155F, M156A, I162F, A164S, A164V, and V166L) and 12 addi-
tional recombinant proteases incorporating mutations in
cofactor NS2B (V75A, V75F, N84A, N84D, N84E, N84L, N84S,
Q86A, Q86E, Q86L, L87A, and L87F). These 24 mutants were
generated by site-directed mutagenesis of a parent construct
WNCF40GlyNS3pro. We have previously shown that expres-
sion of recombinant proteaseWNCF40GlyNS3pro yields a sol-
uble protein that can be purified in high concentration (7). The
purified mutant proteases were run on 12% SDS-PAGE (not
shown) to confirm expression and purification of the desired
27-kDa product (7).
We first evaluated the kinetics of substrate processing by
WNV protease mutants with tetrapeptide and hexapeptide
substrates. The 24 mutant proteases were tested against the
optimized tetrapeptide substrate Ac-LKKR-pNA, and 10 were
also tested against the hexapeptide substrate Ac-LQYTKR-
pNA based on the native NS2B/NS3 cleavage site. Kinetic
parameters (Table 3) for these mutant proteases showed that
most had impaired function compared with wild type enzyme,
with only the conservative NS2B-L87F and polar charged
NS2B-Q86Emutants retaining comparable catalytic efficiency.
In particular, it is notable that NS2B-Q86 participates in a
hydrogen bondwith the charged P3 Lys of inhibitor in the crys-
tal structure, suggesting that the Q86E mutant might enhance
this interaction. However, Km is not significantly higher than
the wild type, and the overall reduction in processing efficiency
is due to a reduction in kcat. This may be due to a reduction in
koff or alternatively due to repositioning of the scissile bond
farther from the catalytic machinery. All WNV protease
mutants also exhibited variable decreases in substrate affinity.
The effects and their implications for substrate-binding inter-
actions are discussed below.
We also examined the kinetics of processing byWNV prote-
ase mutants on the truncated N-capped tripeptide substrate
FIGURE 4. Natural and unnatural amino acids used in P1, P2, and P3
mutant substrate synthesis.
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2-naphthoyl-KKR-pNA (Table 4). Docking of the substrate
2-naphthoyl-KKR-pNA into the crystal structure ofWNV pro-
tease yielded two possible substrate conformations. The
-strand substrate conformation orients the 2-naphthoyl
group in a hydrophobic S4 subsite in the enzyme, bounded by
NS3 residues Val-154 and Ile-155 and the NS2B cofactor resi-
duesVal-75, Val-77, andLeu-87, whereas a turn-like conforma-
tion positions the 2-naphthoyl substituent over the P1 arginine
of the substrate. To identify which of these is more likely, we
tested one relevant NS3 mutant (V154F) and two separate rel-
evant NS2B mutants (L87A and L87F). The V154F and L87A
mutations caused similarly dramatic reductions in kcat and
minor increases in Km, whereas L87F resulted in a similar Km
and only a 3-fold decrease in kcat. Although these results show
that the V154F and L87Amutations have a large effect on proc-
essing of substrates with a naphthoyl at P4, those substrates are
still relatively efficiently processed by the L87F mutant prote-
ase, suggesting that Phe-87 may make a - interaction that
stabilizes naphthoyl binding at S4.
To investigate the hypothesis that the residue at NS2B-84
contributes to substrate binding and provides flavivirus NS3/
NS2B proteases with specificity for either Lys or Arg at P2, the
wild type WNV recombinant protease and the NS2B-N84D/
N84E/N84Smutant proteases were tested against the tetrapep-
tide substrates Ac-LKKR-pNA and Ac-LKRR-pNA (Table 5).
The comparative enzyme kinetic parameters show that the
N84Smutation resulted in a 4-fold decrease inKmwhen P2was
Lys and a 2-fold increase inKmwhen P2was Arg. This supports
observations that Asn-84 (native toWNV) bindsmore strongly
to a P2 Lys, whereas Ser-84 (native to Den) bindsmore strongly
to a P2 Arg. Against both substrates the N84S mutation caused
a decrease in catalytic efficiency, 2-fold against Ac-LKKR-
pNA and as much as 15-fold against Ac-LKRR-pNA, translat-
ing in both cases to about an 8-fold decrease in catalytic effi-
ciency (kcat/Km) versus wild type enzyme.
Similarly, the substitution ofN84D (native to JE,MVE, ZIKV,
andBSQV) produced amutant proteasewith a 2-fold higherKm
for Ac-LKKR-pNA and a 2–3-fold lower Km for Ac-LKRR-
pNA, whereas the kcat was unaffected for the former substrate
but about 6-fold lower for the latter substrate. The overall effect
was a 2-fold decrease in catalytic efficiency for both substrates
following this enzymemutation. Comparison between the sub-
strates reveals an almost 4-fold higher kcat and a 2-fold higher
catalytic efficiency, kcat/Km for Ac-LKKR-pNA compared with
Ac-LKRR-pNA, indicating a preference for a P2 Lys (predomi-
nantly present in native cleavage sequences for JE, MVE, ZIKV,
and BSQV).
The N84Emutation (native to YF) produced amutant pro-
tease with a slightly higher catalytic efficiency for a P2 Arg
(present in YF native cleavage sequences). However, the
TABLE 3
Site-directed mutant enzyme kinetics
Enzyme kinetics were obtained using the in vitro enzyme assay and Ac-LKKR-pNA and Ac-LQYTKR-pNA as substrates with each data point representing the mean of
triplicate measurements S.E.
Mutant AcLKKR-pNA AcLQYTKR-pNAKm kcat kcat/Km Km kcat kcat/Km
M s1 M1 s1 M s1 M1 s1
Wild type 54.6 5.1 1.644 0.041 30,117 2248 199 22 0.266 0.007 1332 118
NS3
T111F 169 13 0.198 0.005 1176 65 376 18 0.051 0.001 135 4
T111L 214 27 0.060 0.003 279 25 617 65 0.018 0.001 30 2
D129A 635 49 0.048 0.002 75 4
D129E 432 18 0.036 0.001 83 2
V154F 263 39 0.057 0.003 216 21
V154L 190 13 0.800 0.018 4223 210 344 28 0.245 0.007 712 40
I155F 207 17 0.733 0.021 3532 196
M156A 164 10 0.778 0.015 4741 210 879 53 0.314 0.010 357 11
I162F 268 28 0.164 0.006 612 43 416 40 0.040 0.002 95 6
A164S 221 23 0.260 0.009 1178 85
A164V 331 15 0.181 0.003 546 16
V166L 96 6 0.638 0.009 6676 309 232 13 0.297 0.005 1282 52
NS2B
V75A 199 10 0.173 0.003 866 30 5318 507 0.164 0.011 31 1
V75F 272 42 0.246 0.017 905 84 809 105 0.091 0.006 113 8
N84A 376 44 0.126 0.007 336 22
N84D 117 5 1.532 0.019 13,109 393
N84E 79.3 4.4 3.027 0.047 38,188 1660
N84L 220 11 0.34 0.006 1543 52
N84S 205 16 0.682 0.019 3333 183
Q86A 258 18 0.367 0.011 1424 61 1203 182 0.127 0.011 105 7
Q86E 77.7 7.3 0.868 0.018 11,182 863
Q86L 148 12 0.973 0.024 6586 381
L87A 434 39 0.070 0.003 161 8
L87F 144 12 1.342 0.033 9345 589 764 53 0.228 0.008 299 11
TABLE 4
Site-directed mutant enzyme kinetics against 2-naphthoyl-Lys-Lys-
Arg-pNA
Enzyme kinetics were obtained using the in vitro enzyme assay against the substrate
2-naphthoyl-KKR-pNA, with each data point representing the mean of triplicate
measurements S.E.
Mutant 2-naphthoyl-KKR-pNAKm kcat kcat/Km
M s1 M1 s1
Wild type 25.4 4.4 1.083 0.055 42,603 5472
NS3-V154F 97.7 6.9 0.0431 0.0013 442 19
NS2B-L87A 88.4 16.0 0.0478 0.0030 541 70
NS2B-L87F 36.9 3.6 0.288 0.008 7796 580
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trend was not the same when comparing substrate affinity,
since both mutants had slightly higher affinity for the Ac-
LKRR-pNA substrate.
The N84S mutant protease was also tested against the trun-
cated substrates 2-naphthoyl-KRR-pNA and 2-naphthoyl-
K(hR)R-pNA in order to examine whether a P2 homoarginine
residue could possibly be recognized with similar efficiency by
either Asn-84 or Ser-84. Both the wild type protease and the
N84S mutant had very similar Km values when assayed against
the 2-naphthoyl-K(hR)R-pNA, suggesting that a P2 homoargi-
nine can bind to Asn-84 or Ser-84 with similar affinity; how-
ever, the catalytic efficiency was decreased by over 20-fold.
Taken together, these results support our earlier work (7, 26),
which suggested that these WNV constructs of the NS2B/NS3
protease aremore efficient enzymes than their dengue counter-
parts at processing their native sequences.
DISCUSSION
Substrate Modifications—One of the most common
approaches to inhibitor development is substrate-based and
begins with substrate optimization. Such approaches for hepa-
titis C virus NS3 protease have led to increases in IC50 values of
over 1000-fold (27, 28). In this study, we began with a tetrapep-
tide substrate and systematically replaced P4, P3, and P2 amino
acids with peptidic and nonpeptidic side chains designed to
map the individual substrate-binding subsites in the protease,
to test the importance of specific enzyme residues that line the
substrate-binding groove, and to enhance substrate affinity and
catalytic efficiency. These solution studies have the potential to
complement structural information provided from solid state
crystal structures of the enzyme, especially providing new
information on the binding of substrate in an extended confor-
mation and induced fit effects, information that is not available
from crystal structures.
A significant improvement in ligand affinity came from
replacements of the “P5” acetyl cap and P4 hydrophobic Leu
with the more rigid, nonpeptidic, 2-naphthoyl group. This
change enhanced substrate affinity, with Km increasing over
2-fold. Docking studies suggested that the bulkier 2-naphthoyl
group may insert deeper into the S4 subsite, with cooperative
movement of both NS3 and NS2B amino acids for optimal
ligand binding. It is likely that furthermodifications of this non-
peptidic P4 cap can produce even higher affinity substrate/in-
hibitor ligands. Incorporating a citrulline into P3 also improved
substrate affinity but reduced kcat. However, when next to a P4
Leu in the substrate, a P3 citrulline had a 10-fold lower Km but
a relatively high kcat. From a drug design standpoint, the obser-
vation that citrulline-containing peptides had higher affinity
than basic amines when 2-naphthoyl was present with poorer
substrate turnover (kcat), while having good turnover in the
presence of Ac-Leu at P4, suggests that a double mutation to a
nonpeptidic entry with no positive charges may be useful for
the preparation of potent inhibitors. Removal of this positive
charge increases drug-like characteristics, such as membrane
permeability. Replacing positive charges at P2 and P1 has so far
not been effective in flavivirus protease inhibitors.
The finding that WNV protease was twice as active against
substrateswith Lys rather thanArg at P2 contrastswith the four
serotypes of dengue protease (21) that weremore active against
substrates with Arg instead of Lys at P2. This confirms predic-
tions from native cleavage sequences and constitutes the first
recognized difference in substrate preference between related
flavivirus proteases. It was previously assumed, based on the
high level of homology within NS3, that an inhibitor developed
against one flaviviral protease could be active against multiple
flaviviruses. Thismay still be possible if a replacement at P2 can
be found that has a high affinity against multiple flavivirus pro-
teases. TheWNVprotease had a substrate affinity (Km) for a P2
homoarginine that was comparable with lysine, and a P2 orni-
thine also gave a relatively high Km and kcat. Neither of these
residues have yet been tested in dengue protease substrates.
Correlation of Mutagenesis Results to Architecture of the
Substrate-binding Cleft—Ile-155 in the crystal structure lies
just beyond the rim of the S1 pocket, with docking of a sub-
strate in the extended -strand conformation suggesting
that Ile-155 may contribute hydrophobic contacts to the
methylene region of the substrate P3 Lys side chain. Muta-
tion of this residue to a bulkier Phe could potentially affect
binding in three ways. First, steric clashes may reduce sub-
strate affinity, seen in the 4-fold reduction in Km and a halv-
ing of kcat. Second, extra bulk at the lip of the S1 pocket may
interfere with entry of the critical P1 Arg of substrates into
the S1 pocket, partially capping it. Third, it is possible that
the aromatic Phe side chain participates in a -cation inter-
action with the charged Lys side chain at P3. Experimental
TABLE 5
Comparison of wild type, NS2B-N84S, NS2B-N84D, and NS2B-N84E enzyme kinetics
Enzyme kinetics were obtained using the in vitro enzyme assay against the Ac-LKKR-pNA, Ac-LKRR-pNA, 2-naphthoyl-KRR-pNA, and 2-naphthoyl-KhRR-pNA sub-
strates. Each data point represents the mean of triplicate measurements S.E.
Mutant Ac-LKKR-pNA Ac-LKRR-pNAKm kcat kcat/Km Km kcat kcat/Km
M s1 M1 s1 M s1 M1 s1
Wild type 54.6 5.1 1.644 0.041 30,117 2248 195 13 2.494 0.053 12,783 596
NS2B-N84S 205 16 0.682 0.019 3333 183 100 8 0.158 0.003 1577 104
NS2B-N84D 117 5 1.532 0.019 13,109 393 69.8 3.3 0.398 0.005 5698 215
NS2B-N84E 79.3 4.4 3.027 0.047 38,188 1660 66.4 4.9 2.707 0.053 40,796 2417
Mutant 2-naphthoyl-KRR-pNA 2-naphthoyl-KhRR-pNAKm kcat kcat/Km Km kcat kcat/Km
M s1 M1 s1 M s1 M1 s1
Wild type 43.4 4.6 0.885 0.040 20,382 1338 26.7 3.7 0.59 0.033 22,066 1953
NS2B-N84S 19.7 5.0 0.151 0.040 7695 1804 29.5 4.1 0.027 0.001 904 93
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evidence suggests that this interaction, if present at all, only
slightly increases affinity.
Hydrophobic residues in NS3 (Val-154 and Met-156) and
NS2B (Leu-87) in the crystal structure form a hydrophobic
patch that probably constitutes S4. The hydrophobic character
of these residues are conserved throughout the Flavivirus
genus. BothWNV and dengueNS3 proteases have a preference
for hydrophobic P4 residues. Substitution of each of these res-
idues gave large losses in substrate affinity, NS3-M156A result-
ing in a 3-fold decrease inKm, NS2B-L87A resulting in an 8-fold
reduction, and even the conservative substitution NS3-V154L
resulting in a 3-fold decrease inKm. Substitution at this sitewith
a bulky Phe had a large effect on substrate affinity; NS3-V154F
gave a 5-fold decrease in Km, whereas NS2B-L87F caused a
3-fold decrease. Each of these substitutions caused a large loss
of catalytic activity except NS2B-L87F, which maintained a
similar catalytic turnover. Modeling suggests that the L87F
mutant directs the Phe side chain away from S4, whereas in the
L87A mutant the small side chain remains directed into the
pocket. This suggests that the S4 pocket is quite flexible and
capable of induced fitting to various P4 substituents, but Leu
may be optimal for efficient association ofNS2B toNS3. Each of
thesemutants was also tested against the hexapeptide substrate
Ac-LQYTKR-pNA and produced similar effects on substrate
affinity and catalytic turnover, reflecting similar binding to the
P4 Tyr as to the P4 Leu.
The Gln at NS2B-86 is within hydrogen bonding distance to
the main chain between the P3 and P4 substrate residues.
Gln-86 is relatively poorly conserved within the Flavivirus
genus but is predominantly polar or positively charged (Glu,
Ser, Lys, Arg, and His; Table 3), suggesting that it may make a
hydrogen bond with the oxygen atom of the P4 backbone car-
bonyl. Substitution of this residue for Ala or Leu produced 5-
and 3-fold losses of substrate affinity, respectively. However,
substitution with a negatively charged Glu produced only a
minor affect on substrate affinity, suggesting that this residue
may participate in hydrogen bonding with the adjacent NS2B
Asn-84. TheQ86A andQ86Lmutants would disrupt this inter-
action and destabilize the region, whereas Q86E would main-
tain it.
The NS2B Val-75 is located in a position that could poten-
tially interact with either P5 or P6. A hydrophobic residue is
completely conserved in this position within the Flavivirus
genus. SubstitutionwithAla resulted in a 4-fold loss inKmwhen
assayed against the tetrapeptide Ac-LKKR-pNA but a large
27-fold loss in Km when assayed against the hexapeptide Ac-
LQYTKR-pNA, supporting the prediction that NS2B Val-75
makes an interaction with P5 or P6. Substitution with an aro-
matic Phe produced a comparable effect on both tetrapeptide
and hexapeptide substrates, 5- and 4-fold losses in Km and 7-
and 3-fold losses in kcat, respectively. It is possible that NS2B
Val-75 is involved in a hydrophobic interaction between the
cofactor and NS3 and contributes to the loss in activity and
affinity.
There is also an interesting correlation between the
mutagenesis results and the binding site for the 2-naphthoyl
substituent. Although the docking of the substrate 2-naphtho-
yl-KKR-pNA into the crystal structure of WNV protease
yielded two possible conformations for the substrate, kinetic
analysis of this substrate against mutant proteases has sug-
gested the -strand substrate conformation to be most likely.
This conformation orients the bulky 2-naphthoyl group by
induced fit into a slightly enlarged hydrophobic P4 subsite.
Since NS3-V154F and NS2B-L87A mutants retained good
affinity for the substrate 2-naphthoyl-KKR-pNA but dramati-
cally affect kcat, there are possibly favorable hydrophobic, aro-
matic-aromatic or - interactions occurring. The decrease in
kcat is presumably due to the slow release (koff) of the N-termi-
nal cleavage product from the enzyme-product complex. It is
unlikely that this naphthoyl residue is exerting its effect on kcat
by displacing the scissile amide bond from its optimal location
due to its significant distance from the catalytic serine residue.
When the important amine/basic side chains of the substrates
are shortened or lengthened (Table 2, entries 10–30),modeling
studies suggest that this causes a displacement of the scissile
bond, the likely cause of the marked drop in kcat for these
substrates.
Substrate Specificity and Cofactor Residue Asn-84—The
cofactor residue at NS2B-84 is associated with a preference for
Lys or Arg at the substrate P2 position. For flaviviral proteases
in which Asn or Asp is at NS2B-84, Lys is predominantly pres-
ent in P2 of the native substrate. When Ser, Thr, or Glu is at
NS2B-84, Arg is preferred at P2 (Table 1).
Various mutations of Asn-84 were tested to further analyze
the effect of this residue on substrate specificity. N84S
decreased affinity of a P2 Lys substrate by 4-fold but increased
affinity of the Arg analogue 2-fold. This came at the expense of
catalytic activity, which decreased by 2- or 20-fold, depending
on the substrate. The altered substrate affinity may prevent
dissociation of the cleavage products that inhibit activity, or
alternatively substrate may bind in a slightly different position
in the mutant enzyme, altering the position of the scissile bond
and affecting catalytic activity.
N84D (native to JE, MVE, ZIKV, and BSQV) gave a higher
catalytic efficiency against substrates containing a P2 Lys,
whereas theN84E (native to YF) gave higher catalytic efficiency
against substrates containing P2 Arg. Because there are subtle
differences in the sizes and shapes of substrate binding pockets
in flavivirus proteases, substitution of a single residue is unlikely
to account for the divergence of specificity, and it is likely to be
these additional differences that add to the specificity for either
Lys or Arg at P2 in substrates.
Although it is unlikely that NS2B-84 contributes the only
difference between the active sites, it does appear to be a major
factor that will need to be addressed in order to develop a broad
spectrum flavivirus protease inhibitor. As an initial attempt to
identify compounds that can bind equally well to either Asn or
Ser at NS2B-84, we found that the tetrapeptide substrate,
2-naphthoyl-KhRR-pNA, with a P2 homoarginine residue
could bind with similar affinity to either the wild type WNV
protease or the NS2B-N84S mutant (Km  26.7  3.7 and
29.5  4.1, respectively). This residue showed a high affinity
that was similar to that for substrate with a P2 lysine binding to
wild type enzyme (Km  25.4  4.4), better than that for sub-
strate with a P2 arginine binding to wild type enzyme (Km 
43.4 4.6) and only slightly worse than for a substratewith a P2
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arginine binding to the mutant N84S protease (Km  19.7 
5.0). Although this substrate has yet to be tested against Den
NS2B/NS3 protease, these results indicate that the P2
homoarginine is likely to bindwell to the P2 pocket of bothDen
andWNV, and therefore it may be a good candidate for incor-
poration into broad spectrum flavivirus protease inhibitors.
Mutations outside the Substrate-binding Cleft—Some muta-
tions were also made in the vicinity of the putative P3 and P4
substrate-binding sites as defined by the homology model.
Within the resolution of theWNVNS2B/NS3 crystal structure,
thesemutated residues were some distance from the active site.
Thr-111 is on the opposite side in the protease to the substrate-
binding cleft but is within hydrogen bonding distance of
the carbon backbone of the NS2B residue Thr-69. The T111L
mutation caused a 4-fold reduction in Km and a 27-fold reduc-
tion in kcat, much greater than a T111Fmutation (3-fold reduc-
tion in Km, 8-fold reduction in kcat). This suggests that the
hydrogen bond contributed by Thr-111 is important for cofac-
tor binding, and in the absence of this, the cofactor binds less
efficiently to protease or in a way that affects catalytic activity
and substrate affinity.
The NS3-I162F mutant produced a large reduction in Km
(5-fold) and kcat (10-fold) against the tetrapeptide substrate but
a lesser reduction against the hexapeptide substrate for bothKm
(2-fold) and kcat (5-fold). Ile-162 is located below the Val-154
and Met-156 residues, which are proposed to constitute the
hydrophobic S4 pocket, and disruption of these residues by the
I162F mutation is likely to affect substrate binding at S4. Both
Ala-164 and Val-166 are in the center of the enzyme, and their
substitution may affect folding of the enzyme. Mutation of
A164S/A164V substantially reduced Km (3- and 6-fold, respec-
tively) and kcat (6- and 9-fold, respectively). The more conserv-
ative substitution of V166L had only a minor effect on process-
ing of both tetrapeptide andhexapeptide substrates. The largest
effect was the 2.5-fold reduction in kcat for Ac-LKKR-pNA.
CONCLUSION
This study has provided valuable new information about the
architecture of the flavivirus NS3 protease in solution and
about interactions made between peptide substrate analogues
and the substrate-binding cleft of the enzyme. Together with
solid state crystal structures of the WNV NS2B/NS3 protease,
this new information helps to provide a firmer basis for rational
drug design. The changes to tetrapeptide substrates described
herein substantially increased enzyme affinity and provide
important clues toward development of substrate-based inhib-
itors of flavivirus proteases.
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Experimental procedures 
 
General Synthetic methods - Fmoc-protected amino acids and resins were obtained from Auspep, 
Novabiochem, ChemImpex, NeoMPS, and PepChem. TFA, piperidine, DIPEA and DMF (peptide 
synthesis grade) were purchased from Auspep. HCTU was purchased from Iris Biotech. Oxone™ was 
purchased from Sigma-Aldrich. All other materials were reagent grade unless otherwise stated. Crude 
peptides were purified by reversed phase HPLC on Vydac C18, 10-15 μm, 300 Å, 50 x 250 mm) and 
Phenomenex Luna C18 (2.2 x 25 cm) columns, using a gradient mixture of solvents (A) 0.1%TFA/water 
and (B) 0.1%TFA/10%water/90%acetonitrile. Analytical HPLC was performed on a Waters system 
equipped with a 717 plus autosampler, 660 controller and a 996 photodiode array detector, using reverse-
phase Phenomenex Luna C8 or C18, 5 μm, 100 Å, 250 x 4.6 mm columns. Purified peptides were 
characterised by analytical HPLC (linear gradient 0-100%B over 30 mins), mass spectrometry and NMR. 
The molecular weight of the peptides (1 mg/mL) was determined by electrospray mass spectrometry on a 
Micromass LCT mass spectrometer. 1H NMR spectra were recorded on samples containing 4 mM peptide 
in DMSO-d6 (550 µL) on Bruker Avance 600 spectrometer at 298 K. Proton resonance assignments were 
determined by TOCSY (80 ms mixing time), DQF-COSY, and NOESY (300 ms mixing time) spectra 
using the sequential assignment method (S1). All spectra were processed on Silicon Graphics R10000 or 
R12000 workstations using XWINNMR 2.1 (Bruker) under Irix or Topspin (Bruker) running under 
Windows (S2). 
 
pNA Substrate Synthesis - pNA substrates were synthesised according to the general method of 
Abbenante (S3). Modifications to the general method were necessary for substrates containing p-
aminoPhe, citrulline, pyridylalanine and 2-naphthoyl residues. p-Aminophe containing p-aminoanilides 
were cleaved from resin using 1% TFA in DCM and were oxidised to the corresponding p-nitroanilides 
using Oxone™ in water/acetonitrile mixtures with the side-chain protecting groups in place. Subsequent 
deprotection with TFA/water/TIPS generated the crude peptides. Citrulline, pyridylalanine and 2-
Naphthoyl-containing substrates were observed to slowly oxidise with excess Oxone in solution. 
2 
Citrulline derivatives gave ornithine-containing by-products, pyridylalanines were converted to their 
corresponding N-oxides, and substrates capped with 2-naphthoic acid were observed to undergo partial 
oxidation of the naphthalene B ring to 1,4-naphthoquinone-6-carboxamide capped substrates.  In all of 
these cases, reduction in the number of equivalents of Oxone™ to 2 and careful monitoring of the 
oxidation reaction by mass spectrometry reduced the incidence of side-products.  
Ac(Nva)KKR-pNA.  This substrate was synthesised on p-phenylenediamine-derivatised TCP resin 
(28) using Fmoc protocols.  Washed and dried peptide on resin (0.25 mmol based on original resin 
loading) was cleaved using trifluoroacetic acid (9.5 mL), water (250 μL) and triisopropylsilane (250 μL) 
for 1 hour and the mixture was filtered, washing the resin with TFA (3x2 mL). The combined filtrates 
were evaporated under a stream of dry nitrogen gas, and the residue was partitioned between ether (20 
mL) and water (20 mL). The aqueous extract containing the peptide p-aminoanilide was oxidised with 
Oxone™ (1.5 mmol) at room temperature with stirring overnight.  The mixture was filtered through a 
0.45 μM filter and purified by preparative reverse-phase HPLC (100% solvent A for 10 minutes to desalt 
the sample followed by a 0-100% B gradient over 20 minutes) followed by freeze drying of pure fractions 
to yield the substrate tris-trifluoroacetate salt as a white powder (161 mg, 62%). (C8 (analytical) Rt = 17.6 
min.).  1H nmr (DMSO-d6) δ 10.67 (s, 1H, pNA-NH), 8.26 (d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 
8.02 (d, 1H, NvaαNH), 8.00 (d, 1H, LysαNH), 7.86 (d, 1H, LysαNH), 7.85 (d, 2H, pNA-ArH), 7.70 (m, 
6H, 2xLyszNH3), 7.62 (t, 1H, ArgεNH), 7.5-6.5 (4H, m, 2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.25 (m, 
1H, LysαCH), 4.22 (m, 1H,LysαCH), 4.17 (m, 1H, NvaαCH), 3.12 (m, 2H, ArgδCH2), 2.74 (m, 4H, 
2xLysεCH2), 1.85 (s, 3H, Ac-CH3), 1.77 (m, 1H, ArgβCH), 1.66 (m, 3H, ArgβCH + 2xLysβCH), 1.61-
1.42 (m, 10H, 2xLysβCH + 2xLysδCH2+ NvaβCH2+ ArgγCH2), 1.38-1.21 (m, 6H, 2xLysγCH2 + 
NvaγCH2), 0.85 (t, 3H, NvaδCH3). ESMS [M+H] = 692.5, [M+2H]/2 = 346.7.  
 
In a similar manner the following substrates were prepared. 
Ac(Nle)KKR-pNA.  (C18 Rt = 17.7 min.): 1H nmr (DMSO-d6) δ 10.67 (s, 1H, pNA-NH), 8.25 (d, 
1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.03 (d, 1H, NleαNH), 7.99 (d, 1H, LysαNH), 7.86 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.70 (m, 6H, 2xLyszNH3), 7.63 (t, 1H, ArgεNH), 7.6-6.7 (4H, m, 
2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.25 (m, 1H, LysαCH), 4.22 (m, 1H,LysαCH), 4.15 (m, 1H, 
NleαCH), 3.12 (m, 2H, ArgδCH2), 2.74 (m, 4H, 2xLysεCH2), 1.85 (s, 3H, Ac-CH3), 1.77 (m, 1H, 
ArgβCH), 1.66 (m, 3H, ArgβCH + 2xLysβCH), 1.63-1.42 (m, 10H, 2xLysβCH + 2xLysδCH2+ 
NleβCH2+ ArgγCH2), 1.37-1.18 (m, 8H, 2xLysγCH2 + NleγCH2 + NleδCH2), 0.84 (t, 3H, NvaεCH3). 
ESMS [M+H] = 706.6, [M+2H]/2 = 353.8.  
AcLKKR-pNA.  (C18 Rt = 17.0 min.): 1H nmr (DMSO-d6) δ 10.67 (s, 1H, pNA-NH), 8.25 (d, 1H, 
ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.03 (d, 1H, LeuαNH), 7.99 (d, 1H, LysαNH), 7.86 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.71 (m, 6H, 2xLyszNH3), 7.63 (t, 1H, ArgεNH), 7.5-6.5 (4H, m, 
2xArgNH2), 4.37 (m, 1H, ArgαCH), 4.25 (m, 1H, LysαCH), 4.23 (m, 1H, LeuαCH), 4.22 (m, 
1H,LysαCH), 3.13 (m, 2H, ArgδCH2), 2.74 (m, 4H, 2xLysεCH2), 1.85 (s, 3H, Ac-CH3), 1.77 (m, 1H, 
ArgβCH), 1.72-1.22 (m, 18H, 8xCH2 + ArgβCH + LeuγCH), 0.88 (t, 3H, LeuδCH3), 0.83 (t, 3H, 
LeuδCH3). ESMS [M+H] = 706.4, [M+2H]/2 = 353.9.  
AcLKRR-pNA.  (C18 Rt = 17.5 min.): 1H nmr (DMSO-d6) δ 10.67 (s, 1H, pNA-NH), 8.28 (d, 1H, 
ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.04 (d, 1H, LeuαNH), 8.01 (d, 1H, LysαNH), 7.89 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.71 (m, 3H, LyszNH3), 7.65 (t, 1H, ArgεNH), 7.59 (t, 1H, ArgεNH), 
7.52-6.53 (4H, m, 2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.27 (m, 1H, ArgαCH), 4.22 (m, 1H, LeuαCH), 
4.21 (m, 1H,LysαCH), 3.12 (m, 2H, ArgδCH2), 3.09 (m, 2H, ArgδCH2), 2.73 (m, 2H, 2xLysεCH2), 1.85 
(s, 3H, Ac-CH3), 1.77 (m, 1H, ArgβCH), 1.72-1.22 (m, 16H, 7xCH2 + ArgβCH + LeuγCH), 0.87 (t, 3H, 
LeuδCH3), 0.83 (t, 3H, LeuδCH3). ESMS [M+H] = 734.5, [M+2H]/2 = 368.0.  
Ac(Chg)KKR-pNA.  (C18 Rt = 18.2 min.): 1H nmr (DMSO-d6) δ 10.66 (s, 1H, pNA-NH), 8.26 
(d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.03 (d, 1H, LysαNH), 7.91 (d, 1H, ChgαNH), 7.85 (d, 2H, 
pNA-ArH), 7.81 (d, 1H, LysαNH), 7.69 (m, 6H, 2xLyszNH3), 7.60 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 
3 
2xArgNH2), 4.37 (m, 1H, ArgαCH), 4.26 (m, 1H, LysαCH), 4.21 (m, 1H,LysαCH), 4.07 (m, 1H, 
ChgαCH), 3.12 (m, 2H, ArgδCH2), 2.73 (m, 4H, 2xLysεCH2), 1.86 (s, 3H, Ac-CH3), 1.77 (m, 1H, 
ArgβCH), 1.72-0.90 (m, 26H, 12xCH2 + ArgβCH + ChgβCH). ESMS [M+H] = 732.5, [M+2H]/2 = 
366.8.  
Ac(Cha)KKR-pNA.  (C18 Rt = 19.0 min.): 1H nmr (DMSO-d6) δ 10.65 (s, 1H, pNA-NH), 8.24 (d, 
1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.03 (d, 1H, ChaαNH), 7.97 (d, 1H, LysαNH), 7.86 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.70 (m, 6H, 2xLyszNH3), 7.63 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 
2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.23 (m, 3H, 2xLysαCH + ChaαCH), 3.12 (m, 2H, ArgδCH2), 2.74 
(m, 4H, 2xLysεCH2), 1.85 (s, 3H, Ac-CH3), 1.77 (m, 1H, ArgβCH), 1.72-1.22 (m, 22H, ArgβCH + 
ArgγCH2 + 2xLysβCH2 + 2xLysγCH2+ 2xLysδCH2+ ChaβCH2 + ChaγCH + 3xChaCH2), 1.16 (m, 1H, 
ChaCH), 1.10 (m, 1H, ChaCH), 0.87 (m, 1H, ChaCH), 0.81 (m, 1H, ChaCH). ESMS [M+H] = 746.5, 
[M+2H]/2 = 373.8.  
Ac(Aib)KKR-pNA.  (C18 Rt = 17.0 min.): 1H nmr (DMSO-d6) δ 10.46 (s, 1H, pNA-NH), 8.37 (s, 
1H, AibαNH), 8.25 (d, 2H, pNA-ArH), 8.01 (br d, 1H, ArgαNH), 7.95 (d, 1H, LysαNH), 7.88 (d, 2H, 
pNA-ArH), 7.77 (d, 1H, LysαNH), 7.71 (m, 6H, 2xLyszNH3), 7.62 (br s 1H, ArgεNH), 7.5-6.7 (4H, m, 
2xArgNH2), 4.34 (m, 1H, ArgαCH), 4.15 (m, 1H, LysαCH), 4.08 (m, 1H,LysαCH), 3.10 (m, 2H, 
ArgδCH2), 2.74 (m, 4H, 2xLysεCH2), 1.86 (s, 3H, Ac-CH3), 1.78 (m, 1H, ArgβCH), 1.73-1.58 (m, 3H, 
ArgβCH + 2xLysβCH), 1.58-1.41 (m, 8H, 2xLysβCH + 2xLysδCH2 + ArgγCH2), 1.40-1.20 (m, 4H, 
2xLysγCH2), 1.32 (s, 3H, AibβCH3), 1.30 (s, 3H, AibβCH3).  ESMS [M+H] = 678.5, [M+2H]/2 = 339.7.  
Ac(Tbg)KKR-pNA.  (C8 Rt = 17.3 min.): 1H nmr (DMSO-d6) δ 10.68 (s, 1H, pNA-NH), 8.27 (d, 
1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.04 (d, 1H, LysαNH), 7.85 (d, 2H, pNA-ArH), 7.84 (d, 1H, 
LysαNH), 7.78 (d, 1H, TbgαNH), 7.68 (m, 6H, 2xLyszNH3), 7.58 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 
2xArgNH2), 4.37 (m, 1H, ArgαCH), 4.27 (m, 1H, LysαCH), 4.21 (m, 1H,LysαCH), 4.17 (d, 1H, 
TbgαCH), 3.12 (m, 2H, ArgδCH2), 2.73 (m, 4H, 2xLysεCH2), 1.90 (s, 3H, Ac-CH3), 1.77 (m, 1H, 
ArgβCH), 1.65 (m, 3H, ArgβCH + 2xLysβCH), 1.60-1.43 (m, 8H, 2xLysβCH + 2xLysδCH2 + ArgγCH2), 
1.31 (m, 4H, 2xLysγCH2), 0.92 (s, 9H, 3xTbgγCH3). ESMS [M+H] = 706.4, [M+2H]/2 = 353.7.  
Ac(Aoc)KKR-pNA.  (C18 Rt = 19.3 min.): 1H nmr (DMSO-d6) δ 10.69 (s, 1H, pNA-NH), 8.28 (d, 
1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.05 (d, 1H, AocαNH), 8.01 (d, 1H, LysαNH), 7.90 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.71 (m, 6H, 2xLyszNH3), 7.65 (t, 1H, ArgεNH), 7.6-6.7 (4H, m, 
2xArgNH2), 4.34 (m, 1H, ArgαCH), 4.24 (m, 1H, LysαCH), 4.21 (m, 1H,LysαCH), 4.14 (m, 1H, 
AocαCH), 3.12 (m, 2H, ArgδCH2), 2.73 (m, 4H, 2xLysεCH2), 1.84 (s, 3H, Ac-CH3), 1.76 (m, 1H, 
ArgβCH), 1.66 (m, 3H, ArgβCH + 2xLysβCH), 1.60-1.42 (m, 12H, 2xLysβCH + 2xLysδCH2 + 
ArgγCH2+ AocβCH2+ AocγCH2), 1.37-1.16 (m, 6H, 2xLysγCH2 + AocδCH2+ AocεCH2+ AoczCH2), 
0.84 (t, 3H, AocCH3). ESMS [M+H] = 734.6, [M+2H]/2 = 367.8.  
2-Naphthoyl-KKR-pNA.  (C18 Rt = 19.1 min.): 1H nmr (DMSO-d6) δ 10.70 (s, 1H, pNA-NH), 
8.65 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.29 (br d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.09 (br d, 
1H, LysαNH), 8.05-7.94 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.70 (m, 6H, 2xLyszNH3), 7.66-7.58 (m, 
3H, ArH + ArgεNH), 7.6-6.7 (4H, m, 2xArgNH2), 4.50 (m, 1H, LysαCH), 4.37 (m, 1H, ArgαCH), 4.33 
(m, 1H, LysαCH), 3.12 (m, 2H, ArgδCH2), 2.79 (m, 2H, LysεCH2), 2.74 (m, 2H, LysεCH2), 1.85-1.26 
(m, 16H, 8xCH2). ESMS [M+H] = 705.5, [M+2H]/2 = 353.2.  
2-Naphthoyl-(Cit)KR-pNA.  (C18 Rt = 20.5 min.): 1H nmr (DMSO-d6) δ 10.70 (s, 1H, pNA-NH), 
8.67 (d, 1H, CitαNH), 8.51 (s, 1H, ArH), 8.28 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.12 (d, 1H, 
LysαNH), 8.06-7.94 (m, 4H, ArH), 7.85 (d, 2H, pNA-ArH), 7.67 (m, 6H, 2xLyszNH3), 7.65-7.58 (m, 2H, 
ArH), 7.56 (t, 1H, ArgεNH), 7.5-6.7 (4H, m, 2xArgNH2), 6.03 (t, 1H, CitεNH), 5.44 (br s, 2H, CitNH2), 
4.50 (m, 1H, CitαCH), 4.39 (m, 1H, ArgαCH), 4.33 (m, 1H, LysαCH), 3.12 (m, 2H, ArgδCH2), 3.01 (m, 
2H, CitδCH2), 2.75 (m, 2H, LysεCH2), 1.83-1.29 (m, 14H, 7xCH2).  ESMS [M+H] = 734.5, [M+2H]/2 = 
367.8.  
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AcL(Cit)KR-pNA.  (C18 Rt = 17.9 min.): 1H nmr (DMSO-d6) δ 10.67 (s, 1H, pNA-NH), 8.24 (m, 
3H, pNA-ArH + ArgαNH), 8.01 (d, 1H, LeuαNH), 7.94 (d, 1H, CitαNH), 7.91 (d, 1H, LysαNH), 7.85 (d, 
2H, pNA-ArH), 7.67 (m, 3H, LyszNH3), 7.55 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 2xArgNH2), 5.98 (t, 1H, 
CitεNH), 5.43 (br s, 2H, CitNH2), 4.38 (m, 1H, ArgαCH), 4.24 (m, 3H, LysαCH + CitαCH + LeuαCH), 
3.12 (m, 2H, ArgδCH2), 2.94 (m, 2H, CitδCH2), 2.74 (m, 2H, LysεCH2), 1.85 (s, 3H, Ac-CH3), 1.76 (m, 
1H, ArgβCH), 1.70-1.23 (m, 16H, ArgβCH + ArgγCH2 + LysβCH2 + LysγCH2 + LysδCH2 + CitβCH2 + 
CitγCH2+ LeuβCH2 + LeuγCH), 0.87 (d, 3H, LeuδCH3), 0.83 (d, 3H, LeuδCH3). ESMS [M+H] = 735.3, 
[M+2H]/2 = 368.2.  
2-Naphthoyl-(Orn)KR-pNA.  (C18 Rt = 19.3 min.): 1H nmr (DMSO-d6) δ 10.70 (s, 1H, pNA-NH), 
8.70 (d, 1H, OrnαNH), 8.52 (s, 1H, ArH), 8.31 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.11 (d, 1H, 
LysαNH), 8.04-7.95 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.71 (m, 6H, LyszNH3 + OrnεNH3), 7.66-
7.59 (m, 3H, ArH + ArgεNH), 7.5-6.8 (4H, m, 2xArgNH2), 4.55 (m, 1H, OrnαCH), 4.37 (m, 1H, 
ArgαCH), 4.34 (m, 1H, LysαCH), 3.12 (m, 2H, ArgδCH2), 2.82 (m, 2H, OrnδCH2), 2.74 (m, 2H, 
LysεCH2), 1.90-1.20 (m, 14H, 7xCH2).  ESMS [M+H] = 691.5, [M+2H]/2 = 346.3.  
AcL(Orn)KR-pNA.  (C18 Rt = 17.2 min.): 1H nmr (DMSO-d6) δ 10.70 (s, 1H, pNA-NH), 8.27 (d, 
1H, ArgαNH), 8.23 (m, 2H, pNA-ArH), 8.06 (d, 1H, OrnαNH), 8.04 (d, 1H, LeuαNH), 7.89 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.76 (m, 6H, OrnεNH3 + LyszNH3), 7.73 (t, 1H, ArgεNH), 7.6-6.8 
(4H, m, 2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.25 (m, 3H, LysαCH + OrnαCH + LeuαCH), 3.12 (m, 2H, 
ArgδCH2), 2.77 (m, 2H, OrnδCH2), 2.73 (m, 2H, LysεCH2), 1.85 (s, 3H, Ac-CH3), 1.81-1.45 (m, 13H, 
6xCH2 + LeuγCH), 1.42 (m, 2H, LeuβCH2), 1.31 (m, 2H, LysγCH2), 0.87 (d, 3H, LeuδCH3), 0.83 (d, 3H, 
LeuδCH3).  ESMS [M+H] = 692.5, [M+2H]/2 = 346.7  
2-Naphthoyl-(3PyA)KR-pNA.  (C18 Rt = 18.9 min.): 1H nmr (DMSO-d6) δ 10.74 (s, 1H, pNA-
NH), 8.78 (d, 1H, 3PyAαNH), 8.62 (s, 1H, ArH), 8.45 (br d, 1H, ArH), 8.39 (s, 1H, ArH), 8.38 (d, 1H, 
ArgαNH), 8.30 (d, 1H, LysαNH), 8.23 (d, 2H, pNA-ArH), 8.02-7.96 (m, 3H, ArH), 7.91 (m, 1H, ArH), 
7.84 (m, 3H, ArH), 7.70-7.57 (m, 5H, ArH + LyszNH3), 7.53 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 
2xArgNH2), 7.41 (m, 3H, ArH), 4.84 (m, 1H, 3PyAαCH), 4.42 (m, 1H, ArgαCH), 4.38 (m, 1H, 
LysαCH), 3.21 (dd, 1H, 3PyAβCH), 3.12 (m, 2H, ArgδCH2), 3.08 (dd, 1H, 3PyAβCH), 2.74 (m, 2H, 
LysεCH2), 1.78 (m, 1H, ArgβCH), 1.71 (m, 1H, LysβCH), 1.66 (m, 1H, ArgβCH), 1.63-1.45 (m, 5H, 
LysβCH + LysδCH2 + ArgγCH2), 1.36 (m, 2H, LysγCH2).  ESMS [M+H] = 725.2, [M+2H]/2 = 363.2.  
AcL(3PyA)KR-pNA.  (C18 Rt = 16.6 min.):  1H nmr (DMSO-d6) δ 10.72 (s, 1H, pNA-NH), 8.50 
(br d, 1H, ArH), 8.48 (br s, 1H, ArH), 8.36 (d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.06 (m, 2H, 
LysαNH), 7.99 (d, 1H, LeuαNH), 7.95 (d, 1H, 3PyAαNH), 7.85 (d, 2H, pNA-ArH), 7.81 (br d, 1H, 
ArH), 7.69 (m, 3H, LyszNH3), 7.61 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 2xArgNH2), 7.43 (m, 1H, ArH), 
4.58 (m, 1H, 3PyAαCH), 4.42 (m, 1H, ArgαCH), 4.30 (m, 1H, LysαCH), 4.14 (m, 1H, LeuαCH), 3.14 
(m, 2H, ArgδCH2), 3.11 (m, 1H, 3PyAβCH), 2.88 (m, 1H, 4PyAβCH), 2.74 (m, 4H, 2xLysεCH2), 1.81 (s, 
3H, Ac-CH3), 1.78 (m, 1H, ArgβCH), 1.66 (m, 2H, ArgβCH + LysβCH), 1.62-1.43 (m, 6H, LysβCH + 
LysδCH2 + LeuγCH + ArgγCH2), 1.38-1.24 (m, 4H, LysγCH2 + LeuβCH2), 0.83 (d, 3H, LeuδCH3), 0.78 
(d, 3H, LeuδCH3). ESMS [M+H] = 726.4, [M+2H]/2 = 363.7.  
AcL(4PyA)KR-pNA.  (C18 Rt = 17.2 min.): 1H nmr (DMSO-d6) δ 10.71 (s, 1H, pNA-NH), 8.53 
(br s, 2H, ArH), 8.35 (d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.02 (m, 2H, 4PyAαNH + LysαNH), 
7.97 (d, 1H, LeuαNH), 7.85 (d, 2H, pNA-ArH), 7.66 (m, 3H, LyszNH3), 7.55 (t, 1H, ArgεNH), 7.5-6.6 
(4H, m, 2xArgNH2), 7.41 (br s, 2H, ArH), 4.62 (m, 1H, 4PyAαCH), 4.41 (m, 1H, ArgαCH), 4.30 (m, 1H, 
LysαCH), 4.14 (m, 1H, LeuαCH), 3.13 (m, 3H, 4PyAβCH + ArgδCH2), 2.91 (m, 1H, 4PyAβCH), 2.74 
(m, 4H, 2xLysεCH2), 1.83 (s, 3H, Ac-CH3), 1.77 (m, 1H, ArgβCH), 1.65 (m, 2H, ArgβCH + LysβCH), 
1.60-1.42 (m, 6H, LysβCH + LysδCH2 + LeuγCH + ArgγCH2), 1.38-1.22 (m, 4H, LysγCH2 + LeuβCH2), 
0.83 (d, 3H, LeuδCH3), 0.77 (d, 3H, LeuδCH3). ESMS [M+H] = 726.8, [M+2H]/2 = 363.7.  
2-Naphthoyl-(hArg)KR-pNA.  (C18 Rt = 20.3 min.): 1H nmr (DMSO-d6) δ 10.65 (s, 1H, pNA-
NH), 8.62 (d, 1H, hArgαNH), 8.50 (s, 1H, ArH), 8.25 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.06-
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7.94 (m, 5H, ArH + LysαNH), 7.84 (d, 2H, pNA-ArH), 7.71-7.59 (m, 5H, LyszNH3 + ArH), 7.52 (br t, 
1H, ArgεNH), 7.48 (br t, 1H, hArgzNH), 7.5-6.5 (8H, m, 2xArgNH2 + 2xhArgNH2), 4.50 (m, 1H, 
hArgαCH), 4.39 (m, 1H, ArgαCH), 4.34 (m, 1H, LysαCH), 3.11 (m, 4H, ArgδCH2 +hArgεCH2), 2.73 
(m, 2H, LysεCH2), 1.87-1.25 (m, 16H, 8xCH2).  ESMS [M+H] = 747.2, [M+2H]/2 = 374.3.  
AcL(hArg)KR-pNA.  (C18 Rt = 17.3 min.): 1H nmr (DMSO-d6) δ 10.68 (s, 1H, pNA-NH), 8.26 (d, 
1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.05 (d, 1H, LeuαNH), 7.99 (d, 1H, hArgαNH), 7.87 (d, 1H, 
LysαNH), 7.85 (d, 2H, pNA-ArH), 7.75 (m, 3H, LyszNH3), 7.71 (t, 1H, ArgεNH), 7.61 (t, 1H, 
hArgzNH), 7.6-6.7 (4H, m, 2xArgNH2), 4.36 (m, 1H, ArgαCH), 4.24(m, 3H, LysαCH + hArgαCH + 
LeuαCH), 3.12 (m, 2H, ArgδCH2), 3.05 (m, 2H, hArgεCH2), 2.73 (m, 4H, 2xLysεCH2), 1.85 (s, 3H, Ac-
CH3), 1.77 (m, 1H, Argβ SMS [M+H] = 748.3, [M+2H]/2 = 374.7.  
AcL(NO2F)KR-pNA.  (C18 Rt = 20.7 min.): 1H nmr (DMSO-d6) δ 10.71 (s, 1H, pNA-NH), 8.35 
(d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.10 (d, 2H, ArH), 8.07 (d, 1H, LysαNH), 7.96 (d, 1H, 
NO2PheαNH), 7.95 (d, 1H, LeuαNH), 7.85 (d, 2H, pNA-ArH), 7.70 (m, 3H, LyszNH3), 7.60 (t, 1H, 
ArgεNH), 7.6-6.5 (4H, m, 2xArgNH2), 7.49 (d, 2H, ArH), 4.61 (m, 1H, NO2PheαCH), 4.41 (m, 1H, 
ArgαCH), 4.30 (m, 1H,LysαCH), 4.14 (m, 1H, LeuαCH), 3.19 (dd, 1H, NO2PheβCH), 3.13 (m, 2H, 
ArgδCH2), 2.94 (dd, 1H, NO2PheβCH), 2.74 (m, 2H, LysεCH2), 1.81 (s, 3H, Ac-CH3), 1.78 (m, 1H, 
ArgβCH), 1.67 (m, 2H, ArgβCH + LysβCH), 1.61-1.46 (m, 5H, LysβCH + ArgγCH2 + LysδCH2), 1.44 
(m, 1H, LeuγCH), 1.32 (m, 2H, LysγCH2), 1.26 (m, 2H, LeuβCH2), 0.81 (d, 3H, LeuδCH3), 0.75 (d, 3H, 
LeuδCH3). ESMS [M+H] = 770.4, [M+2H]/2 = 385.7.  
AcL(NH2F)KR-pNA.  (C18 Rt = 17.2 min.): 1H nmr (DMSO-d6) δ 10.68 (s, 1H, pNA-NH), 8.28 
(d, 1H, ArgαNH), 8.24 (m, 3H, pNA-ArH), 7.99 (d, 1H, LeuαNH), 7.93 (d, 1H, LysαNH), 7.85 (d, 2H, 
pNA-ArH), 7.81 (d, 1H, NH2PheαNH), 7.67 (m, 3H, LyszNH3), 7.55 (t, 1H, ArgεNH), 7.5-6.6 (4H, m, 
2xArgNH2), 7.00 (br s, 2H, ArH), 6.69 (br s, 2H, ArH), 4.40 (m, 2H, ArgαCH + NH2PheαCH), 4.28 (m, 
1H, LysαCH), 4.17 (m, 1H, LeuαCH), 3.13 (m, 2H, ArgδCH2), 2.92 (br d, 1H, NH2PheβCH2), 2.74 (m, 
2H, LysεCH2), 2.70 (br d, 1H, NH2PheβCH2), 1.82 (s, 3H, Ac-CH3), 1.78 (m, 1H, ArgβCH), 1.67 (m, 2H, 
ArgβCH + LysβCH), 1.61-1.45 (m, 6H, ArgγCH2 + LysβCH+ LysδCH2 + LeuγCH), 1.37-1.26 (m, 4H, 
LeuβCH2 + LysγCH2 ), 0.84 (d, 3H, LeuδCH3), 0.79 (d, 3H, LeuδCH3).  ESMS [M+H] = 740.4, 
[M+2H]/2 = 370.8.  
2-Naphthoyl-K(Cit)R-pNA.  (C18 Rt = 19.4 min.): 1H nmr (DMSO-d6) δ 10.64 (s, 1H, pNA-NH), 
8.67 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.25 (d, 1H, ArgαNH), 8.22 (d, 2H, pNA-ArH), 8.07 (br d, 1H, 
CitαNH), 8.05-7.95 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.70 (m, 3H, LyszNH3), 7.65-7.56 (m, 3H, 
ArH + ArgεNH), 7.5-6.6 (4H, m, 2xArgNH2), 6.01 (t, 1H, CitεNH), 5.43 (br s , 2H, CitNH2), 4.50 (m, 
1H, LysαCH), 4.35 (m, 1H, ArgαCH), 4.33 (m, 1H, CitαCH), 3.11 (m, 2H, ArgδCH2), 2.97 (m, 2H, 
CitδCH2), 2.79 (m, 2H, LysεCH2), 1.87-1.33 (m, 14H, 7xCH2).  ESMS [M+H] = 734.1, [M+2H]/2 = 
367.8.  
2-Naphthoyl-K(Orn)R-pNA.  (C18 Rt = 18.3 min.): 1H nmr (DMSO-d6) δ 10.73 (s, 1H, pNA-NH), 
8.67 (d, 1H, LysαNH), 8.52 (s, 1H, ArH), 8.31 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.18 (br d, 1H, 
OrnαNH), 8.05-7.95 (m, 4H, ArH), 7.85 (d, 2H, pNA-ArH), 7.79 (m, 6H, OrnzNH3 + LyszNH3), 7.74 (t, 
1H, ArgεNH), 7.65-7.58 (m, 2H, ArH), 7.6-6.8 (4H, m, 2xArgNH2), 4.51 (m, 1H, LysαCH), 4.38 (m, 2H, 
ArgαCH + OrnαCH), 3.12 (m, 2H, ArgδCH2), 2.81 (m, 4H, OrnδCH2 + LysεCH2), 1.86-1.34 (m, 14H, 
7xCH2).  ESMS [M+H] = 691.2, [M+2H]/2 = 346.2.  
2-Naphthoyl-KRR-pNA.  (C18 Rt = 18.4 min.): 1H nmr (DMSO-d6) δ 10.71 (s, 1H, pNA-NH), 
8.68 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.31 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.12 (br d, 1H, 
LysαNH), 8.04-7.95 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.74 (m, 3H, LyszNH3), 7.68 (t, 1H, 
ArgεNH), 7.65-7.59 (m, 2H, ArH), 7.6-6.7 (8H, m, 4xArgNH2), 4.50 (m, 1H, LysαCH), 4.36 (m, 2H, 
2xArgαCH), 3.11 (m, 4H, 2xArgδCH2), 2.79 (m, 2H, LysεCH2), 1.84-1.35 (m, 14H, 7xCH2).  ESMS 
[M+H] = 733.2, [M+2H]/2 = 367.2.  
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2-Naphthoyl-K(hArg)R-pNA.  (C18 Rt = 18.6 min.): 1H nmr (DMSO-d6) δ 10.70 (s, 1H, pNA-
NH), 8.66 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.29 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.09 (d, 
1H, hArgαNH), 8.05-7.94 (m, 4H, ArH), 7.85 (d, 2H, pNA-ArH), 7.75 (m, 3H, LyszNH3), 7.69(t, 1H, 
ArgεNH), 7.66-7.59 (m, 2H, ArH), 7.6-6.7 (8H, m, 2xArgNH2 + 2xhArgNH2), 4.50 (m, 1H, LysαCH), 
4.37 (m, 1H, ArgαCH), 4.33 (m, 1H, hArgαCH), 3.12 (m, 2H, ArgδCH2), 3.05 (m, 2H, hArgδCH2), 2.79 
(m, 2H, LysεCH2), , 1.85-1.26 (m, 16H, 8xCH2).  ESMS [M+H] = 747.2, [M+2H]/2 = 374.3.  
2-Naphthoyl-LK(AcK)R-pNA.  (C18 Rt = 20.5 min.): 1H nmr (DMSO-d6) δ 10.64 (s, 1H, pNA-
NH), 8.67 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.26 (d, 1H, ArgαNH), 8.22 (d, 2H, pNA-ArH), 8.05-
7.94 (m, 5H, ArH + LysαNH), 7.84 (d, 2H, pNA-ArH), 7.79 ( t, 1H, LyzzNH), 7.70 (m, 3H, LyszNH3), 
7.65-7.56 (m, 3H, ArH + ArgεNH), 7.5-6.7 (4H, m, 2xArgNH2), 4.50 (m, 1H, LysαCH), 4.35 (m, 1H, 
ArgαCH), 4.29 (m, 1H, LysαCH), 3.11 (m, 2H, ArgδCH2), 2.98 (m, 2H, LysεCH2), 2.79 (m, 2H, 
LysεCH2), 1.86-1.22 (m, 16H, 8xCH2), 1.77 (s, 3H, Ac-CH3).  ESMS [M+H] = 747.2, [M+2H]/2 = 374.3.  
2-Naphthoyl-K(NH2F)R-pNA.  (C18 Rt = 19.6 min.): 1H nmr (DMSO-d6) δ 10.66 (s, 1H, pNA-
NH), 8.65 (d, 1H, LysαNH), 8.49 (s, 1H, ArH), 8.35 (d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.05-
7.98 (m, 3H, ArH), 7.94 (m,2H, ArfH + NH2FαNH), 7.86 (d, 2H, pNA-ArH), 7.69 (m, 3H, LyszNH3), 
7.66-7.53 (m, 3H, ArH + ArgεNH), 7.5-6.6 (4H, m, 2xArgNH2), 7.05 (m, 2H, ArH), 6.67 (m, 2H, ArH), 
4.54 (m, 1H, NH2FαCH), 4.43 (m, 1H, LysαCH), 4.38 (m, 1H, ArgαCH), 3.11 (m, 2H, ArgδCH2), 2.97 
(dd, 1H, NH2FβCH), 2.77 (m, 3H, LysεCH2 + NH2FβCH), 1.85-1.26 (m, 10H, 5xCH2).  ESMS [M+H] = 
739.3, [M+2H]/2 = 370.4.  
2-Naphthoyl-K(Nle)R-pNA.  (C18 Rt = 22.7 min.): 1H nmr (DMSO-d6) δ 10.64 (s, 1H, pNA-NH), 
8.68 (d, 1H, LysαNH), 8.51 (s, 1H, ArH), 8.27 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.05-7.95 (m, 
5H, ArH + NleαNH), 7.84 (d, 2H, pNA-ArH), 7.71 (m, 3H, LyszNH3), 7.65-7.58 (m, 3H, ArH + 
ArgεNH), 7.6-6.7 (4H, m, 2xArgNH2), 4.50 (m, 1H, LysαCH), 4.36 (m, 1H, ArgαCH), 4.31 (m, 1H, 
NleαCH), 3.11 (m, 2H, ArgδCH2), 2.79 (m, 2H, LysεCH2), 1.87-1.20 (m, 16H, 8xCH2), 0.81 (t, 3H, 
NleεCH3.  ESMS [M+H] = 690.4, [M+2H]/2 = 345.9.  
2-Naphthoyl-KFR-pNA.  (C18 Rt = 22.8 min.): 1H nmr (DMSO-d6) δ 10.66 (s, 1H, pNA-NH), 
8.65 (d, 1H, LysαNH), 8.48 (s, 1H, ArH), 8.41 (d, 1H, ArgαNH), 8.24 (d, 2H, pNA-ArH), 8.05-7.97 (m, 
4H, ArH + PheαNH), 7.95 (dd, 1H, ArH), 7.86 (d, 2H, pNA-ArH), 7.69 (m, 6H, 2xLyszNH3), 7.66-7.57 
(m, 3H, ArH + ArgεNH), 7.5-6.7 (4H, m, 2xArgNH2), 7.23 (br d, 2H, ArH), 7.14 (br t, 2H, ArH), 7.10 (br 
t, 1H, ArH), 4.62 (m, 1H, PheαCH), 4.41 (m, 1H, LysαCH), 4.39 (m, 1H, ArgαCH), 3.12 (m, 2H, 
ArgδCH2), 3.08 (dd, 1H, PheβCH), 2.86 (dd, 1H, PheβCH), 2.75 (m, 2H, LysεCH2), 1.84-1.20 (m, 10H, 
5xCH2).  ESMS [M+H] = 724.2, [M+2H]/2 = 362.6.  
2-Naphthoyl-(Orn)(Orn)R-pNA.  (C18 Rt = 18.2 min.): 1H nmr (DMSO-d6) δ 10.73 (s, 1H, pNA-
NH), 8.69 (d, 1H, OrnαNH), 8.52 (s, 1H, ArH), 8.34 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.20 (br 
d, 1H, OrnαNH), 8.04-7.96 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.73 (m, 6H, 2xOrnεNH3), 7.66-7.59 
(m, 3H, ArH + ArgεNH), 7.5-6.7 (4H, m, 2xArgNH2), 4.57 (m, 1H, OrnαCH), 4.38 (m, 2H, ArgαCH+ 
OrnαCH), 3.12 (m, 2H, ArgδCH2), 2.90-2.74 (m, 4H, 2xOrnδCH2), 1.90-1.43 (m, 12H, 6xCH2).  ESMS 
[M+H] = 677.1, [M+2H]/2 = 339.3.  
2-Naphthoyl-(Cit)(Orn)R-pNA.  (C18 Rt = 19.4 min.): 1H nmr (DMSO-d6) δ 10.71 (s, 1H, pNA-
NH), 8.66 (d, 1H, CitαNH), 8.51 (s, 1H, ArH), 8.31 (d, 1H, ArgαNH), 8.23 (d, 2H, pNA-ArH), 8.18 (br 
d, 1H, OrnαNH), 8.04-7.95 (m, 4H, ArH), 7.84 (d, 2H, pNA-ArH), 7.70 (m, 3H, OrnεNH3), 7.65-7.59 (m, 
2H, ArH), 7.5-6.6 (4H, m, 2xArgNH2), 6.07 (t, 1H, CitεNH), 5.49 (br s, 2H, CitNH2), 4.51 (m, 1H, 
CitαCH), 4.40 (m, 1H, ArgαCH), 4.37 (m, 1H, OrnαCH), 3.11 (m, 2H, ArgδCH2), 3.01(m, 2H, 
CitδCH2), 2.80 (m, 2H, OrnδCH2), 1.84-1.41 (m, 12H, 6xCH2).  ESMS [M+H] = 720.6, [M+2H]/2 = 
360.6.  
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Table S1. Primers used for site-directed mutagenesis 
 
Primer Sequence 
WNNS3-111.R 5’-CCGGACGTTCTTAACGTTCTTGCCAGG-3’ 
WNNS3-T111L.F 5’-TTAAGAACGTCCGGCTGAAACCAGGGGTG-3’ 
WNNS3-T111F.F 5’-TTAAGAACGTCCGGTTCAAACCAGGGGTG-3’ 
WNNS3-154,155.R 5’-TCCATTGCCATAAAGCCCAATCACATCACC-3’ 
WNNS3-V154F.F 5’-CTTTATGGCAATGGATTCATAATGCCCAAC-3’ 
WNNS3-V154L.F 5’-CTTTATGGCAATGGACTCATAATGCCCAAC-3’ 
WNNS3-I155F.F 5’-CTTTATGGCAATGGAGTCTTCATGCCCAACGGC-3’ 
WNNS3-M156A.F 5’-ATAGCGCCCAACGGCTCATACATAAGC-3’ 
WNNS3-M156A.R 5’-GTTGGGCGCTATGACTCCATTGCCATA-3’ 
WNNS3-162,164,166.R 5’-GTATGAGCCGTTGGGCATTATGACTCCATT-3’ 
WNNS3-I162F.F 5’-CCAACGGCTCATACTTCAGCGCGATAGTG-3’ 
WNNS3-A164S.F 5’-CCAACGGCTCATACATAAGCTCGATAGTGCAG-3’ 
WNNS3-A164V.F 5’-CCAACGGCTCATACATAAGCGTGATAGTGCAG-3’ 
WNNS3-V166L.F 5’-CCAACGGCTCATACATAAGCGCGATACTGCAGGGTGAA-3’ 
WNCF40-V75A.F 5’-AGAGCTGATGTGCGGCTTGATGATGATG-3’ 
WNCF40-V75A.R 5’-CGCACATCAGCTCTTTCGCTTGAGCCT-3’ 
WNCF40-75.R 5’-TCTTTCGCTGGAGCCTGTAATTTCTGCAT-3’ 
WNCF40-V75L.F 5’-TCGAGCGAAAGACTTGATGTGCGGC-3’ 
WNCF40-V75F.F 5’-TCGAGCGAAAGATTTGATGTGCGGC-3’ 
WNCF40-N84A.F 5’-GGAGCCTTCCAGCTCATGAATGATCCA-3’ 
WNCF40-N84A.R 5’-CTGGAAGGCTCCATCATCATCAAGCCG-3’ 
WNCF40-84.R 5’-TCCATCATCATCAAGCCGCACATCAAC-3’ 
WNCF40-N84D.F  5’-CTTGATGATGATGGAGATTTCCAGCTCATG-3’ 
WNCF40-N84E.F  5’-CTTGATGATGATGGAGAATTCCAGCTCATG-3’ 
WNCF40-N84L.F 5’-CTTGATGATGATGGACTCTTCCAGCTCATG-3’ 
WNCF40-N84S.F 5’-CTTGATGATGATGGATCATTCCAGCTCATG-3’ 
WNCF40-Q86A.F 5’-TTCGCGCTCATGAATGATCCAGGTGCT-3’ 
WNCF40-Q86A.R 5’-CATGAGCGCGAAGTTTCCATCATCATCA-3’ 
WNCF40-86,87.R 5’-GAAGTTTCCATCATCATCAAGCCGCACAT-3’ 
WNCF40-Q86L.F 5’-GATGATGGAAACTTCCTGCTCATGAATGATCC-3’ 
WNCF40-Q86E.F 5’-GATGATGGAAACTTCGAGCTCATGAATGATCC-3’ 
WNCF40-L87F.F 5’-GATGATGGAAACTTCCAGTTTATGAACGATCC-3’ 
WNCF40-L87A.F 5’-CAGGCCATGAATGATCCAGGTGCTCCT-3’ 
WNCF40-L87A.R 5’-CATTCATGGCCTGGAAGTTTCCATCATC-3’ 
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Table S2.  List of interacting residues from NS2B/NS 3 WNV-Pr predicted by molecular docking studies 
to interact with peptide substrate residues 
 
Substrate Residue NS3 residues NS2B Residues 
P1’ Ala 36  
 His 51  
 Thr 52  
 Thr 132  
 Ser 135  
   
P1 His 51  
 Asp 129  
 Tyr 130  
 Pro 131  
 Thr 132  
 Ser 135  
 Tyr 150  
 Gly 151  
 Tyr 161  
   
P2 His 51 Gly 83 
 Asp 75 Asn 84 
 Gly 151  
 Asn 152  
   
P3 Gly 153  
 Val 154  
 Ile 155  
 Tyr 161  
   
P3 Phe 116 Phe 85 
 Gly 153 Gln 86 
 Val 174 Leu 87 
 Ile 175  
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